 Connection
Andrea Gaedigk to Treatment Outcome
This is a "connection" page, showing publications Andrea Gaedigk has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Bunka M, Wong G, Kim D, Edwards L, Austin J, Doyle-Waters MM, Gaedigk A, Bryan S. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis. Psychiatry Res. 2023 03; 321:115102.
Score: 0.046
-
Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, Gaedigk A, Pepper MS. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics. 2017 Apr; 18(5):433-443.
Score: 0.030
-
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M?ller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07; 102(1):37-44.
Score: 0.030
-
S?nchez-Mart?n A, S?nchez-Iglesias S, Garc?a-Berrocal B, Lorenzo C, Gaedigk A, Isidoro-Garc?a M. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics. 2016 08; 17(12):1291-3.
Score: 0.029
-
S?nchez-Iglesias S, Garc?a-Solaesa V, Garc?a-Berrocal B, Sanchez-Mart?n A, Lorenzo-Romo C, Mart?n-Pinto T, Gaedigk A, Gonz?lez-Buitrago JM, Isidoro-Garc?a M. Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (Baltimore). 2016 Feb; 95(6):e2473.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|